Fortress Biotech Pref Preferred Stock Net Asset
| FBIOP Preferred Stock | USD 5.12 0.15 2.85% |
Fortress Biotech Pref fundamentals help investors to digest information that contributes to Fortress Biotech's financial success or failures. It also enables traders to predict the movement of Fortress Preferred Stock. The fundamental analysis module provides a way to measure Fortress Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fortress Biotech preferred stock.
Fortress |
Fortress Biotech Pref Company Net Asset Analysis
Fortress Biotech's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Fortress Biotech Net Asset | 396.5 M |
Most of Fortress Biotech's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fortress Biotech Pref is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Fortress Biotech Pref has a Net Asset of 396.5 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States preferred stocks is notably lower than that of the firm.
Fortress Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fortress Biotech's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the preferred stocks which would be a good addition to a portfolio. Peer analysis of Fortress Biotech could also be used in its relative valuation, which is a method of valuing Fortress Biotech by comparing valuation metrics of similar companies.Fortress Biotech is currently under evaluation in net asset category among its peers.
Fortress Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fortress Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fortress Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Fortress Fundamentals
| Return On Equity | -1.43 | ||||
| Return On Asset | -0.35 | ||||
| Profit Margin | (1.17) % | ||||
| Operating Margin | (2.63) % | ||||
| Current Valuation | 2.58 B | ||||
| Shares Outstanding | 56.68 M | ||||
| Shares Owned By Institutions | 1.80 % | ||||
| Number Of Shares Shorted | 245 | ||||
| Price To Sales | 1.36 X | ||||
| Revenue | 68.79 M | ||||
| Gross Profit | (85.66 M) | ||||
| EBITDA | (46.05 M) | ||||
| Net Income | (164.83 M) | ||||
| Cash And Equivalents | 248.77 M | ||||
| Cash Per Share | 2.31 X | ||||
| Total Debt | 46.56 M | ||||
| Debt To Equity | 0.81 % | ||||
| Current Ratio | 2.85 X | ||||
| Book Value Per Share | 0.57 X | ||||
| Cash Flow From Operations | (116.54 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (0.86) X | ||||
| Number Of Employees | 173 | ||||
| Beta | 1.9 | ||||
| Market Capitalization | 107.79 M | ||||
| Total Asset | 396.5 M | ||||
| Z Score | 1.2 | ||||
| Annual Yield | 0.12 % | ||||
| Net Asset | 396.5 M |
About Fortress Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fortress Biotech Pref's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fortress Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fortress Biotech Pref based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Fortress Preferred Stock Analysis
When running Fortress Biotech's price analysis, check to measure Fortress Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fortress Biotech is operating at the current time. Most of Fortress Biotech's value examination focuses on studying past and present price action to predict the probability of Fortress Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fortress Biotech's price. Additionally, you may evaluate how the addition of Fortress Biotech to your portfolios can decrease your overall portfolio volatility.